In another signal of the appetite among investors for companies applying artificial intelligence to drug discovery, Pathos AI has gathered an impressive $365 million in fourth-round financing as it ...

A British marketing agency ranked among Europe's fastest-growing businesses is planning to float on the London Stock Exchange later this month, The Mail on Sunday understands. Pathos Communications, ...

From infomercials to political canvassing to appeals for coveted roles, the most compelling rhetoric uses a mix of ethos, pathos, and logos. These techniques encompass a wide spectrum of human ...

Increased global competition has fuelled disruption and competition in almost all industries. There are notable exceptions, however, where businesses are not spoilt for choice. One of those is in the ...

Why you can trust What Hi-Fi? Our expert team reviews products in dedicated test rooms, to help you make the best choice for your budget. Find out more about how we test. Pathos’s Inpol Remix MkII is ...

Ross Bonaime is the Senior Film Editor at Collider. He is a Virginia-based critic, writer, and editor who has written about all forms of entertainment for Paste Magazine, Brightest Young Things, ...

Story: Having left behind his turbulent fixer life, Rana Naidu (Rana Daggubati) hopes for peace with his family. But when a powerful billionaire pulls him back into the shadows, Rana must fight to ...

You can keep up with everything related to the Switch 2’s launch and beyond right here. You might find it kind of sad to put your hard-earned Switch 2 into a protective case. To me, it’s freeing. Sure ...

Segment 1: Ilyce Glink, owner of Think Glink Media and Best Money Moves, joins John Williams to talk about the strength of the spring housing market, and to break down the data released in the IRS ...

Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised $365 million in a late-stage funding. The company didn’t disclose the ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Pathos AI, the biotech drug developer spun out of Tempus ...

Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of solid tumor drugs sourced from Novo Nordisk and Prelude Therapeutics. The ...